<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Biomed Res</journal-id><journal-id journal-id-type="iso-abbrev">Adv Biomed Res</journal-id><journal-id journal-id-type="publisher-id">ABR</journal-id><journal-title-group><journal-title>Advanced Biomedical Research</journal-title></journal-title-group><issn pub-type="ppub">2277-9175</issn><issn pub-type="epub">2277-9175</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25221752</article-id><article-id pub-id-type="pmc">4162080</article-id><article-id pub-id-type="publisher-id">ABR-3-149</article-id><article-id pub-id-type="doi">10.4103/2277-9175.137831</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Long-term results of pleurodesis in malignant pleural effusions: Doxycycline vs Bleomycin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rafiei</surname><given-names>Rahmatollah</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Yazdani</surname><given-names>Behnam</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Ranjbar</surname><given-names>Sayed Milad</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Torabi</surname><given-names>Zahra</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Asgary</surname><given-names>Sedigheh</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Najafi</surname><given-names>Somayeh</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib><contrib contrib-type="author"><name><surname>Keshvari</surname><given-names>Mahtab</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib></contrib-group><aff id="aff1">Islamic Azad University, Najafabad Branch, Najafabad, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Isfahan Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Rahmatollah Rafiei, Islamic Azad University Najafabad Branch, Najafabad, Isfahan, Iran. E-mail: <email xlink:href="rahmatollahrafiei@yahoo.com">rahmatollahrafiei@yahoo.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>31</day><month>7</month><year>2014</year></pub-date><volume>3</volume><elocation-id>149</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>05</day><month>5</month><year>2013</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2014 Rafiei.</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><sec id="st1"><title>Background:</title><p>The aim of this study was to compare the response of doxycycline and bleomycin in pleurodesis of malignant pleural effusions.</p></sec><sec id="st2"><title>Materials and Methods:</title><p>The radiologic and clinical responses of doxycycline and bleomycin in pleurodesis of malignant pleural effusions were compared in this randomized clinical trial. Forty-two patients were randomized to receive either bleomycin 45 mg or doxycycline 600 mg as the sclerotherapy agent. Chest X-rays were taken before and after intervention, 10 days and 2 months later to compare the radiologic response. Dyspnea and other side effects, before and after intervention, 10 days and 2 months later were recorded and compared. Chi-square test was applied to analyze the data.</p></sec><sec id="st3"><title>Results:</title><p>The prevalence of dyspnea and its different severities, 10 days and 2 months after intervention were significantly different (<italic>P</italic> &#x0003c; 0.05) between the two groups. Analysis of pleural effusions revealed a significant difference (<italic>P</italic> &#x0003c; 0.05) between Doxycycline vs. Bleomycin 2 months after the intervention. Three months after pleurodesis, only one patient in bleomycin group needed pleural fluid drainage.</p></sec><sec id="st4"><title>Conclusion:</title><p>Pleural effusions did not change with use of doxycycline and bleomycin in short time but long-term results of doxycycline sclerotherapy was better than bleomycin sclerotherapy in malignant pleural effusions that was supported by this study. However, additional studies with larger sample size are necessary to confirm the results.</p></sec></abstract><kwd-group><kwd>Bleomycin</kwd><kwd>doxycycline</kwd><kwd>malignant pleural effusion</kwd><kwd>sclerotherapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Malignant pleural effusion is commonly exudative type diagnosed cytologically[<xref rid="ref1" ref-type="bibr">1</xref>] and is a significant public health problem.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] It deteriorates the quality of life in patients with cancer.[<xref rid="ref1" ref-type="bibr">1</xref><xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref5" ref-type="bibr">5</xref>] Its management depends on underlying malignancy and the extent of disease.[<xref rid="ref6" ref-type="bibr">6</xref>] Treatment goals for these patients should focus on relief or elimination of dyspnea, restoration of normal activity and function, minimization or elimination of hospitalization, and efficient use of medical care resources.[<xref rid="ref2" ref-type="bibr">2</xref><xref rid="ref3" ref-type="bibr">3</xref>] The standard management approach begins with a diagnostic and/or therapeutic thoracentesis. If the effusion recurs, other options include repeated thoracentesis, tube thoracostomy with chemical pleurodesis, placement of an indwelling cuffed, tunneled pleural catheter with or without pleurodesis, medical thoracoscopy, or video-assisted thoracoscopic surgery with pleurodesis.[<xref rid="ref7" ref-type="bibr">7</xref>] Some are treated with systematic chemotherapy whereas most are preterminal event and need palliative therapy to minimize discomfort and cost.[<xref rid="ref8" ref-type="bibr">8</xref><xref rid="ref9" ref-type="bibr">9</xref>] It is done through tube thoracostomy and sclerotherapy, thoracentesis, or pleural shunts. Sclerosing agent is an important factor in success of sclerotherapy. There is no universal agreement on the most effective and least harmful agent in inducing pleurodesis in malignant pleural effusion.[<xref rid="ref10" ref-type="bibr">10</xref>] Although doxycycline has been widely used to treat malignant pleural effusions,[<xref rid="ref11" ref-type="bibr">11</xref><xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] its long-term effects in comparison with bleomycin have been less studied. The aim of this study is to compare the therapeutic effects of two medications on malignant pleural effusions.</p></sec><sec sec-type="materials|methods" id="sec1-2"><title>MATERIALS AND METHODS</title><p>This study was a randomized clinical trial to compare the radiologic and clinical responses of two different sclerotherapy agents, doxycycline and bleomycin, in pleurodesis of malignant pleural effusions. Inclusion criteria included symptomatic patients with cytologically proved malignant pleural effusions hospitalized in our hospital over a period of 22 months. Exclusion criteria included allergy to doxycycline or bleomycin, past history of sclerotherapy, systematic chemotherapy immediately prior to or in the next 2 months after sclerotherapy, and unwillingness to continue the study. The study was approved by ethics committee of the hospital. Written informed consent was signed by all patients. The technique of pleurodesis has been explained elsewhere.[<xref rid="ref16" ref-type="bibr">16</xref><xref rid="ref17" ref-type="bibr">17</xref>]</p><p>After fluid evacuation, the patient was randomized to treatment with either bleomycin 45 mg or doxycycline 600 mg. The latter was mixed with 50 ml normal saline and 10 ml of 1% lidocaine. The therapeutic sclerosing agent was injected in the pleural space through the tube. Then, it was closed to wall suction for 1 hour while the patient was seated for 1 hour. It is demonstrated that doxycycline rapidly diffuses in pleural space and there is no need to rotate the patient.[<xref rid="ref18" ref-type="bibr">18</xref>] Thereafter, the tube was reopened to wall suction. When the drainage was less than 100 mL/day, the drainage catheter was removed. Upright chest X-rays (CXRs), posteroanterior and lateral views, were taken before and after the procedure. CXRs were repeated 10 days and 2 months later to compare the fluid levels. The radiologic response was defined by the fluid level observed in costophrenic and vertebrophrenic angles. No more accumulation of pleural fluid was determined as mild effusion. Accumulation of fluid in less than 50% of pulmonary fields was set as moderate pleural effusion, whereas fluid accumulation covering more than 50% of pulmonary fields was determined as severe pleural effusion. The amount and frequency of fluid drainage up to 3 months after the procedure were registered. The clinical response was set based on the prevalence of different severities of dyspnea before and after intervention. It was classified as no dyspnea, mild dyspnea (difficult respiration during heavy physical activities), moderate dyspnea (dyspnea during regular daily physical activities), and severe dyspnea (difficult respiration at rest). The radiologic and clinical response rates between the two groups were compared using Chi-square test. SPSS software, version 10 (SPSS Inc., Chicago, IL, USA) was used to analyze the data. <italic>P</italic> values less than 0.05 were considered significant. Complications of the procedure including dyspnea, local chest pain, and fever were recorded before and after the procedure; 10 days and 2 months later. Supportive measures were applied to resolve the symptoms after sclerotherapy.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref>]</p></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Forty-two patients with malignant pleural effusion were randomized to sclerotherapy with either doxycycline or bleomycin. The mean age of patients was 68 years. Thirty patients were male. No patient expired or lost to follow-up within 3 months after sclerotherapy.</p><p>Fourteen male and seven female patients with a mean age of 66.5 years received doxycycline sclerotherapy. Ten men and no woman had past history of smoking. The minimum, maximum, and mean values of tobacco exposure were 10, 30, and 21 pack year, respectively. Eleven patients had metastatic carcinoma. Others had mesothelioma (three patients), squamous cell carcinoma (three patients), bronchogenic carcinoma (two patients), and lymphoma (two patients). Complications of doxycycline sclerotherapy included dyspnea [<xref ref-type="table" rid="T1">Table 1</xref>], local chest pain in 15 patients and fever in seven patients. The mean time of having chest pain was 2.5 days after the intervention. The mean time of appearance of fever was 11 h after the procedure.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Prevalence of different severities of dyspnea, before and after the procedure, and 10 days and 2 months later in each group</p></caption><graphic xlink:href="ABR-3-149-g001"/></table-wrap><p>Sixteen male and five female patients with a mean age of 69 years received bleomycin sclerotherapy. Fourteen men and no woman had past history of smoking. The minimum, maximum, and mean values of tobacco exposure were 3, 35, and 21.5 pack year; respectively. Thirteen patients had metastatic carcinoma. Others had mesothelioma (two patients), squamous cell carcinoma (one patient), bronchogenic carcinoma (three ones), and lymphoma (two patients). Complications of bleomycin sclerotherapy included dyspnea [<xref ref-type="table" rid="T1">Table 1</xref>], local chest pain in 17 patients and fever in five patients. The mean time of having chest pain was 1 day after the intervention. The mean time of appearance of fever was 3 h after the procedure.</p><p>Prevalence of dyspnea was not significantly different between the two groups before and immediately after sclerotherapy. But, the prevalence of dyspnea and its different severities, 10 days and 2 months after intervention were significantly different between the two groups [<xref ref-type="table" rid="T1">Table 1</xref>].</p><p>Prevalence of mild, moderate, and severe pleural effusions was not significantly different between doxycycline and bleomycin sclerotherapy before and immediately after the procedure, and also 10 days later [<xref ref-type="table" rid="T2">Table 2</xref>]. But, 2 months after intervention, the difference in radiologic response rates between the two groups was significant. In other words at this time, 67% of patients in doxycycline group showed mild pleural effusion, whereas 71% of patients in bleomycin group had moderate effusion [<xref ref-type="table" rid="T2">Table 2</xref>]. Three months after sclerotherapy, nobody in doxycycline group and one patient in bleomycin group had pleural fluid drainage (<italic>P</italic> = 0.5). There was also no difference in frequency of chest pain and fever and their durations between the two groups.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Prevalence of different severities of pleural effusion, before and after the procedure, and 10 days and 2 months later in each group</p></caption><graphic xlink:href="ABR-3-149-g002"/></table-wrap><p>Prevalence of different severities of dyspnea and pleural effusion based on underlying malignancies 2 months after sclerotherapy in the two groups are presented in Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Prevalence of different severities of dyspnea based on underlying malignancy, 2 months after sclerotherapy in each group</p></caption><graphic xlink:href="ABR-3-149-g003"/></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Prevalence of different severities of pleural effusions based on underlying malignancy, 2 months after sclerotherapy in each group</p></caption><graphic xlink:href="ABR-3-149-g004"/></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>A malignant pleural effusion (MPE) is defined by the presence of cancer cells in the pleural space.[<xref rid="ref22" ref-type="bibr">22</xref>] Most malignant pleural effusions in patients older than 60 years are induced by metastatic carcinoma.[<xref rid="ref4" ref-type="bibr">4</xref>] Similarly, the mean age of patients in the current study was 68 years and over 57% of their malignant pleural effusions were caused by metastatic carcinoma. The most common side-effect of intrapleural doxycycline or bleomycin has been chest pain.[<xref rid="ref19" ref-type="bibr">19</xref><xref rid="ref20" ref-type="bibr">20</xref><xref rid="ref21" ref-type="bibr">21</xref><xref rid="ref23" ref-type="bibr">23</xref><xref rid="ref24" ref-type="bibr">24</xref>] Over 76% of patients in the present study experienced chest pain after pleurodesis.</p><p>This study evaluated the radiologic and clinical responses of two different sclerotherapy agents, doxycycline and bleomycin, in pleurodesis of malignant pleural effusions. Different studies reported various response rates based on underlying malignancies and the extent of disease.[<xref rid="ref12" ref-type="bibr">12</xref><xref rid="ref13" ref-type="bibr">13</xref><xref rid="ref14" ref-type="bibr">14</xref><xref rid="ref15" ref-type="bibr">15</xref><xref rid="ref16" ref-type="bibr">16</xref>] No dyspnea, mild dyspnea. and moderate dyspnea; 10 days and 2 months after sclerotherapy, were significantly less frequent in doxycycline group compared with bleomycin group in the current study. Although no one in any group demonstrated severe pleural effusion 2 months after intervention, the doxycycline group revealed significantly less frequent moderate pleural effusion compared with the bleomycin group. There were no significant differences in other measurements between the two groups. Bleomycin is generally much more expensive than doxycycline.[<xref rid="ref4" ref-type="bibr">4</xref><xref rid="ref25" ref-type="bibr">25</xref>] Given the lower cost of the latter, its well-tolerance and its satisfactory radiologic and clinical response after 2 months in patients with malignant pleural effusion, this study supports the long term role of doxycycline over bleomycin in sclerotherapy of malignant pleural effusions. Further investigations with larger sample sizes are needed to confirm the results of this study.</p></sec><sec sec-type="conclusion" id="sec1-5"><title>CONCLUSION</title><p>Pleural effusions did not change with use of doxycycline and bleomycin in short time but long-term results of doxycycline sclerotherapy was better than bleomycin sclerotherapy in malignant pleural effusions that was supported by this study. However, additional studies with larger sample size are necessary to confirm the results.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors gratefully acknowledge authorities at the Islamic Azad University Najafabad branch for financial support of this study.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Islamic Azad University Najafabad Branch.</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> None declared.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchi</surname><given-names>E</given-names></name><name><surname>Teixeira</surname><given-names>LR</given-names></name><name><surname>Vargas</surname><given-names>FS</given-names></name></person-group><article-title>Management of malignancy-associated pleural effusion: Current and future treatment strategies</article-title><source>Am J Respir Med</source><year>2003</year><volume>2</volume><fpage>261</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">14720007</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><collab>American Thoracic Society</collab><article-title>Management of malignant pleural effusions</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>162</volume><fpage>1987</fpage><lpage>2001</lpage><pub-id pub-id-type="pmid">11069845</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>G</given-names></name><name><surname>Neville</surname><given-names>E</given-names></name></person-group><article-title>Management of malignant pleural effusions</article-title><source>Thorax</source><year>2000</year><volume>55</volume><fpage>981</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11083880</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>CO</given-names></name><name><surname>Gora</surname><given-names>ML</given-names></name></person-group><article-title>Pleural effusions: Pathophysiology and management</article-title><source>Ann Pharmacother</source><year>1994</year><volume>28</volume><fpage>894</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">7524816</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimitriadis</surname><given-names>KA</given-names></name></person-group><article-title>Malignant pleural effusions</article-title><source>Arch Oncol</source><year>2001</year><volume>9</volume><fpage>2</fpage></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielsa</surname><given-names>S</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Rodriguez-Panadero</surname><given-names>F</given-names></name><name><surname>Taberner</surname><given-names>T</given-names></name><name><surname>Salud</surname><given-names>A</given-names></name><name><surname>Porcel</surname><given-names>JM</given-names></name></person-group><article-title>Tumor type influences the effectiveness of pleurodesis in malignant effusions</article-title><source>Lung</source><year>2011</year><volume>189</volume><fpage>151</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21331598</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name></person-group><article-title>Pleurodesis for malignant pleural effusions</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><fpage>CD002916</fpage><pub-id pub-id-type="pmid">14973997</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benko</surname><given-names>I</given-names></name><name><surname>Molnar</surname><given-names>TF</given-names></name><name><surname>Horvath</surname><given-names>OP</given-names></name></person-group><article-title>Palliative treatment of malignant pleural effusions by video-assisted thoracoscopic surgery</article-title><source>Acta Chir Hung</source><year>1999</year><volume>38</volume><fpage>131</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">10596313</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Baumann</surname><given-names>MH</given-names></name><name><surname>Maskell</surname><given-names>NA</given-names></name><name><surname>Waterer</surname><given-names>GW</given-names></name><name><surname>Eaton</surname><given-names>TE</given-names></name><name><surname>Davies</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Pleurodesis practice for malignant pleural effusions in five English-speaking countries: Survey of pulmonologists</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>2229</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">14665505</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>C</given-names></name><name><surname>Sedrakyan</surname><given-names>A</given-names></name><name><surname>Browne</surname><given-names>J</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Treasure</surname><given-names>T</given-names></name></person-group><article-title>The evidence on the effectiveness of management for malignant pleural effusion: A systematic review</article-title><source>Eur J Cardiothorac Surg</source><year>2006</year><volume>29</volume><fpage>829</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16626967</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>G</given-names></name><name><surname>Neville</surname><given-names>E</given-names></name><name><surname>Duffy</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>N</given-names></name></person-group><collab>Pleural Diseases Group, Standards of Care Committee British Thoracic Society</collab><article-title>BTS guidelines for the management of malignant pleural effusions</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>ii29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">12728148</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzdzal</surname><given-names>J</given-names></name><name><surname>Sladek</surname><given-names>K</given-names></name><name><surname>Wasowski</surname><given-names>D</given-names></name><name><surname>Soja</surname><given-names>J</given-names></name><name><surname>Szlubowski</surname><given-names>A</given-names></name><name><surname>Reifland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Talc powder vs doxycycline in the control of malignant pleural effusion: A prospective, randomized trial</article-title><source>Med Sci Monit</source><year>2003</year><volume>9</volume><fpage>PI54</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12824959</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilaceroglu</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Hawthorne</surname><given-names>ML</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Stathopoulos</surname><given-names>GT</given-names></name><name><surname>Lane</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Oral forms of tetracycline and doxycycline are effective in producing pleurodesis</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3750</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16304343</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikensoy</surname><given-names>O</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Donnelly</surname><given-names>E</given-names></name><name><surname>Stathopoulos</surname><given-names>GT</given-names></name><name><surname>Lane</surname><given-names>KB</given-names></name><name><surname>Light</surname><given-names>RW</given-names></name></person-group><article-title>Combination therapy with intrapleural doxycycline and talc in reduced doses is effective in producing pleurodesis in rabbits</article-title><source>Chest</source><year>2005</year><volume>128</volume><fpage>3735</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">16304341</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerimagic</surname><given-names>Z</given-names></name><name><surname>Guska</surname><given-names>S</given-names></name><name><surname>Pilav</surname><given-names>I</given-names></name><name><surname>Banjanovic</surname><given-names>B</given-names></name></person-group><article-title>The using doxycycline in procedure chemical pleurodesis of malignancy pleural effusion</article-title><source>Med Arh</source><year>2006</year><volume>60</volume><fpage>360</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17297849</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcel</surname><given-names>JM</given-names></name><name><surname>Salud</surname><given-names>A</given-names></name><name><surname>Nabal</surname><given-names>M</given-names></name><name><surname>Vives</surname><given-names>M</given-names></name><name><surname>Esquerda</surname><given-names>A</given-names></name><name><surname>Rodriguez-Panadero</surname><given-names>F</given-names></name></person-group><article-title>Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions</article-title><source>Support Care Cancer</source><year>2006</year><volume>14</volume><fpage>475</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16404570</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elpern</surname><given-names>EH</given-names></name><name><surname>Krueger</surname><given-names>J</given-names></name><name><surname>Kimsey</surname><given-names>J</given-names></name><name><surname>Silver</surname><given-names>M</given-names></name></person-group><article-title>The technique of pleurodesis</article-title><source>J Crit Illn</source><year>1994</year><volume>9</volume><fpage>1105</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">10150700</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dryzer</surname><given-names>SR</given-names></name><name><surname>Allen</surname><given-names>ML</given-names></name><name><surname>Strange</surname><given-names>C</given-names></name><name><surname>Sahn</surname><given-names>SA</given-names></name></person-group><article-title>A comparison of rotation and nonrotation in tetracycline pleurodesis</article-title><source>Chest</source><year>1993</year><volume>104</volume><fpage>1763</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8252959</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DiBardino</surname><given-names>DJ</given-names></name><name><surname>Vanatta</surname><given-names>JM</given-names></name><name><surname>Fagan</surname><given-names>SP</given-names></name><name><surname>Awad</surname><given-names>SS</given-names></name></person-group><article-title>Acute respiratory failure after pleurodesis with doxycycline</article-title><source>Ann Thorac Surg</source><year>2002</year><volume>74</volume><fpage>257</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12118779</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Jun Na</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>KB</given-names></name><name><surname>Light</surname><given-names>RW</given-names></name></person-group><article-title>The short-term administration of Ketoprofen does not decrease the effect of Pleurodesis induced by talc or Doxycycline in rabbits</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><fpage>963</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17056242</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fyfe</surname><given-names>AJ</given-names></name><name><surname>McKay</surname><given-names>P</given-names></name></person-group><article-title>Toxicities associated with bleomycin</article-title><source>J R Coll Physicians Edinb</source><year>2010</year><volume>40</volume><fpage>213</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21127762</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heffner</surname><given-names>JE</given-names></name><name><surname>Klein</surname><given-names>JS</given-names></name></person-group><article-title>Recent advances in the diagnosis and management of malignant pleural effusions</article-title><source>Mayo Clin Proc</source><year>2008</year><volume>83</volume><fpage>235</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">18241636</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><article-title>Bleomycin in malignant pleural effusion. Choose talc pleurodesis</article-title><source>Prescrire Int</source><year>2011</year><volume>20</volume><fpage>291</fpage><pub-id pub-id-type="pmid">22216541</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker-Renard</surname><given-names>PB</given-names></name><name><surname>Vaughan</surname><given-names>LM</given-names></name><name><surname>Sahn</surname><given-names>SA</given-names></name></person-group><article-title>Chemical pleurodesis for malignant pleural effusions</article-title><source>Ann Intern Med</source><year>1994</year><volume>120</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8250457</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dikensoy</surname><given-names>O</given-names></name><name><surname>Light</surname><given-names>RW</given-names></name></person-group><article-title>Alternative widely available, inexpensive agents for pleurodesis</article-title><source>Curr Opin Pulm Med</source><year>2005</year><volume>11</volume><fpage>340</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15928503</pub-id></element-citation></ref></ref-list></back></article>